Literature DB >> 33860176

Discriminative Stimulus Effects of Substituted Tryptamines in Rats.

Michael B Gatch1, Adam Hoch1, Theresa M Carbonaro2.   

Abstract

Novel synthetic compounds have been available for decades as quasi-legal alternatives to controlled substances. The hallucinogen-like effects of eight novel substituted tryptamines were evaluated to determine their potential abuse liability. Male Sprague-Dawley rats were trained to discriminate 2,5-dimethoxy-4-methylamphetamine (DOM, 0.5 mg/kg, i.p., 30 min) from saline. 4-Acetoxy-N,N-diethyltryptamine (4-AcO-DET), 4-hydroxy-N-methyl-N-ethyltryptamine (4-OH-MET), 4-hydroxy-N,N-diethyltryptamine (4-OH-DET), 4-acetoxy-N-methyl-N-isopropyltryptamine (4-AcO-MiPT), 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT), 4-hydroxy-N,N-dimethyltryptamine (4-OH-DMT, psilocin), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT), and 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT) were tested for their ability to substitute for the discriminative stimulus effects of DOM. All test compounds fully substituted for DOM with potencies less than or equal to that of DOM. 4-OH-MET, 4-OH-DET, 4-OH-DMT, and 4-AcO-DMT decreased response rate at doses that fully substituted. Because the test compounds produced DOM-like discriminative stimulus effects, they may have similar abuse liability as DOM. 4-Acetoxy substituted compounds were less potent than 4-hydroxy substituted compounds, and the N,N-diisopropyl compounds were less potent than the dimethyl, diethyl, N-methyl-N-ethyl, and N-methyl-N-isopropyl compounds.
© 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 33860176      PMCID: PMC8033599          DOI: 10.1021/acsptsci.0c00173

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  31 in total

1.  Multicomponent LC-MS/MS screening method for detection of new psychoactive drugs, legal highs, in urine-experience from the Swedish population.

Authors:  Yasir Al-Saffar; Niclas Nikolai Stephanson; Olof Beck
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-05-07       Impact factor: 3.205

2.  Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.

Authors:  J B Blair; D Kurrasch-Orbaugh; D Marona-Lewicka; M G Cumbay; V J Watts; E L Barker; D E Nichols
Journal:  J Med Chem       Date:  2000-11-30       Impact factor: 7.446

3.  Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis.

Authors:  Álvaro José Palma-Conesa; Mireia Ventura; Liliana Galindo; Francina Fonseca; Marc Grifell; Pol Quintana; Iván Fornís; Cristina Gil; Magí Farré; Marta Torrens
Journal:  J Psychoactive Drugs       Date:  2017-06-01

4.  Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats.

Authors:  Michael B Gatch; Margaret A Rutledge; Theresa Carbonaro; Michael J Forster
Journal:  Psychopharmacology (Berl)       Date:  2009-03-14       Impact factor: 4.530

5.  A Fatality Related to Two Novel Hallucinogenic Compounds: 4-Methoxyphencyclidine and 4-Hydroxy-N-methyl-N-ethyltryptamine.

Authors:  Iain M McIntyre; Amber Trochta; Ray D Gary; Alina Storey; Jennifer Corneal; Bethann Schaber
Journal:  J Anal Toxicol       Date:  2015-08-10       Impact factor: 3.367

6.  Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function.

Authors:  Amy J Eshleman; Michael J Forster; Katherine M Wolfrum; Robert A Johnson; Aaron Janowsky; Michael B Gatch
Journal:  Psychopharmacology (Berl)       Date:  2013-10-19       Impact factor: 4.530

Review 7.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

8.  Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.

Authors:  Anna Rickli; Olivier D Moning; Marius C Hoener; Matthias E Liechti
Journal:  Eur Neuropsychopharmacol       Date:  2016-05-20       Impact factor: 4.600

9.  Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.

Authors:  Theresa M Carbonaro; Matthew W Johnson; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2020-06-05       Impact factor: 4.530

10.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

View more
  1 in total

1.  Chemoenzymatic Synthesis of 5-Methylpsilocybin: A Tryptamine with Potential Psychedelic Activity.

Authors:  Janis Fricke; Alexander M Sherwood; Adam L Halberstadt; Robert B Kargbo; Dirk Hoffmeister
Journal:  J Nat Prod       Date:  2021-03-05       Impact factor: 4.803

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.